|
Apr 26
|
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
|
|
Apr 26
|
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
|
|
Apr 26
|
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
|
|
Apr 19
|
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
|
|
Apr 12
|
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
|
|
Apr 10
|
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
|
|
Apr 8
|
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
|
|
Apr 8
|
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
|
|
Apr 5
|
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
|
|
Apr 3
|
Q4 2023 Ocugen Inc Earnings Call
|
|
Apr 2
|
Ocugen (OCGN) Q4 2023 Earnings Call Transcript
|
|
Apr 2
|
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
|
|
Apr 1
|
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
|
|
Apr 1
|
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
|
|
Mar 25
|
3 Stocks Under $5 Ready to Outpace the Market
|
|
Mar 18
|
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
|
|
Mar 13
|
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
|
|
Mar 7
|
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street
|
|
Mar 6
|
Ocugen to Present at Investing in Cures Summit
|
|
Feb 28
|
Ocugen Clinical Showcase Webcast Now Available
|